ArticleDiscover oncology2025
Identification of cellular senescence-associated genes for predicting the diagnosis, prognosis and immunotherapy response in lung adenocarcinoma via a 113-combination machine learning framework.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BIP orchestrates bidirectional ER protein trafficking via co-chaperone complexes.Cellular & molecular biology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a prevalent malignant tumor of the respiratory system, with high incidence and mortality rates. Cellular senescence (CS) widely affects the tumor microenvironment (TME) and tumor growth, and is related to the invasion and immune escape of tumor cells. This study aims to develop a robust CS-related signature of LUAD.
methodsUsing the GSE140797, GSE42458, GSE75037, and GSE85841 datasets, in combination with cellular senescence databases, 75 LUAD CS-related differentially expressed genes (LUAD-CSDEGs) were identified through the weighted gene co-expression network analysis (WGCNA) method. Subsequently, we developed a novel machine learning framework that incorporated 12 machine learning algorithms and their 113 combinations to construct a LUAD CS-related signature (LUAD-CSRS), which were assessed in both training and validation cohorts. A LUAD-CSRS-integrated nomogram was constructed to provide a quantitative tool for predicting prognosis in clinical practice. Finally, the difference of immune infiltration and response to immunotherapy in patients with high and low risk of LUAD were evaluated.
resultsBased on a 113-combination machine learning framework, we finally identified a LUAD-CSRS containing eight genes: RECQL4, TIMP1, ANLN, SFN, MDK, KIF2C, AGR2, ITGB4. We also confirmed that it was significantly associated with survival, immune cell infiltration, prognosis, and response to immunotherapy in LUAD patients. Additionally, we found it is related to the activation of immune responses and may be involved in regulating the balance between immune cells in the TME.
conclusionIn summary, our study constructed a novel LUAD-CSRS, which is not only expected to be a powerful tool for assisting diagnosis and prognosis evaluation of LUAD, but also may provide guidance for personalized immunotherapy programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.